Literature DB >> 20407854

Knockdown of SOD1 sensitizes the CD34+ CML cells to imatinib therapy.

Li Liu1, Renan Chen, Siyong Huang, Yanlan Wu, Guohui Li, Qiang Liu, Dandan Yin, Yingmin Liang.   

Abstract

Leukemia stem cell is thought to be one of the leading causes of imatinib resistance and the resultant relapse of chronic myelogenous leukemia (CML). Eradicating the leukemia stem cells holds the promise of CML treatment. In this study, we found that the CD34+ subpopulation in the CML cell line K562 had a higher expression of SOD1 than that in the CD34 negative cells. Knockdown of SOD1 in CD34+ cells had no significant effects on cell survival and growth, while it sensitized the CD34+ cells to imatinib therapy. N-acetyl-L cysteine (NAC) blocked the pro-apoptotic effects of SOD1 knockdown, suggesting the antioxidant effects of SOD1 was essential for the resistance of CD34+ cells to imatinib therapy. In summary, our results suggest that antagonizing the enhanced endogenous antioxidant activity in leukemia stem cells sheds lights on CML therapy.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20407854     DOI： 10.1007/s12032-010-9529-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  16 in total

Review 1.  Posttranslational modifications in Cu,Zn-superoxide dismutase and mutations associated with amyotrophic lateral sclerosis.

Authors:  Yoshiaki Furukawa; Thomas V O'Halloran
Journal:  Antioxid Redox Signal       Date:  2006 May-Jun       Impact factor: 8.401

2.  TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia.

Authors:  Kazuhito Naka; Takayuki Hoshii; Teruyuki Muraguchi; Yuko Tadokoro; Takako Ooshio; Yukio Kondo; Shinji Nakao; Noboru Motoyama; Atsushi Hirao
Journal:  Nature       Date:  2010-02-04       Impact factor: 49.962

Review 3.  Monitoring disease response to tyrosine kinase inhibitor therapy in CML.

Authors:  Timothy P Hughes; Susan Branford
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

Review 4.  Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells.

Authors:  Kazuhito Naka; Teruyuki Muraguchi; Takayuki Hoshii; Atsushi Hirao
Journal:  Antioxid Redox Signal       Date:  2008-11       Impact factor: 8.401

Review 5.  Oxidative stress in the regulation of normal and neoplastic hematopoiesis.

Authors:  Saghi Ghaffari
Journal:  Antioxid Redox Signal       Date:  2008-11       Impact factor: 8.401

6.  PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.

Authors:  Artur Gontarewicz; Stefan Balabanov; Gunhild Keller; Jens Panse; Philippe Schafhausen; Carsten Bokemeyer; Walter Fiedler; Jürgen Moll; Tim H Brümmendorf
Journal:  Leuk Res       Date:  2008-06-02       Impact factor: 3.156

7.  BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death.

Authors:  A McGahon; R Bissonnette; M Schmitt; K M Cotter; D R Green; T G Cotter
Journal:  Blood       Date:  1994-03-01       Impact factor: 22.113

8.  FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress.

Authors:  Zuzana Tothova; Ramya Kollipara; Brian J Huntly; Benjamin H Lee; Diego H Castrillon; Dana E Cullen; Elizabeth P McDowell; Suzan Lazo-Kallanian; Ifor R Williams; Christopher Sears; Scott A Armstrong; Emmanuelle Passegué; Ronald A DePinho; D Gary Gilliland
Journal:  Cell       Date:  2007-01-26       Impact factor: 41.582

9.  Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors.

Authors:  H Konig; M Holtz; H Modi; P Manley; T L Holyoake; S J Forman; R Bhatia
Journal:  Leukemia       Date:  2008-02-14       Impact factor: 11.528

Review 10.  Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.

Authors:  Daniel J DeAngelo; Eyal C Attar
Journal:  Leuk Lymphoma       Date:  2010-03
View more
  5 in total

Review 1.  Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches.

Authors:  Cristóbal Aguilar-Gallardo; Emily Cecilia Rutledge; Ana M Martínez-Arroyo; Juan José Hidalgo; Santiago Domingo; Carlos Simón
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

2.  miR-153 sensitized the K562 cells to As2O3-induced apoptosis.

Authors:  Li Liu; Renan Chen; Siyong Huang; Yanlan Wu; Guohui Li; Bei Zhang; Qiang Liu; Dandan Yin; Yingmin Liang
Journal:  Med Oncol       Date:  2011-01-26       Impact factor: 3.064

Review 3.  Mitochondrial membrane potential and reactive oxygen species in cancer stem cells.

Authors:  Bei-bei Zhang; Dao-gang Wang; Fen-fen Guo; Chao Xuan
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

Review 4.  Manganese superoxide dismutase in cancer prevention.

Authors:  Delira Robbins; Yunfeng Zhao
Journal:  Antioxid Redox Signal       Date:  2013-07-18       Impact factor: 8.401

5.  Quantitative phenotyping-based in vivo chemical screening in a zebrafish model of leukemia stem cell xenotransplantation.

Authors:  Beibei Zhang; Yasuhito Shimada; Junya Kuroyanagi; Noriko Umemoto; Yuhei Nishimura; Toshio Tanaka
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.